AbbVie is paying $150 million upfront for rights to Chinese biotech FutureGen Biopharmaceutical’s FG-M701, described as a next-generation antibody that binds to tumour necrosis factor-like ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback